
Contents

Preface	v
Contributors	xi
PART I. INTRODUCTION	
1 Overview of Novel Anticancer Drug Targets John K. Buolamwini and Haregewein Assefa	3
PART II. KINASE INHIBITOR DISCOVERY PROTOCOLS	
2 Biomarker Assays for Phosphorylated MAP Kinase: <i>Their Utility for Measurement of MEK Inhibition</i> Judith S. Sebolt-Leopold, Keri Van Becelaere, Kenneth Hook, and Roman Herrera	31
3 Assays for Cyclin-Dependent Kinase Inhibitors Adrian M. Senderowicz and Tyler Lahusen	39
4 Identifying Inhibitors of ATM and ATR Kinase Activities Jann N. Sarkaria	49
PART III. ANGIOGENESIS AND METASTASIS PROTOCOLS	
5 The Rat Aortic Ring Assay for In Vitro Study of Angiogenesis Ronald S. Go and Whyte G. Owen	59
6 Real Time In Vivo Quantitation of Tumor Angiogenesis Gregory I. Frost and Per Borgström	65
7 Use of Tumor-Activated Hepatic Stellate Cell as a Target for the Preclinical Testing of Anti-Angiogenic Drugs Against Hepatic Tumor Development Elvira Olaso and Fernando Vidal-Vanaclocha	79
8 Cell Motility, Adhesion, Homing, and Migration Assays in the Studies of Tyrosine Kinases Martin Sattler, Elizabeth Quackenbush, and Ravi Salgia	87
9 Inflammatory Response of Tumor-Activated Hepatic Sinusoidal Endothelium as a Target for the Screening of Metastasis Chemopreventive Drugs Lorea Mendoza and Fernando Vidal-Vanaclocha	107

10	Binding Assay for Selectins <i>Jianing Zhang and Michiko N. Fukuda</i>	117
11	Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody–Interleukin-2 Immunocytokine <i>Jacquelyn A. Hank, Jean E. Surfus, Jacek Gan, Amy Ostendorf, Stephen D. Gillies, and Paul M. Sondel</i>	123
PART IV. IMMUNOHISTOCHEMICAL ASSAYS IN THE CLINICAL SETTING		
12	Immunohistochemical Determination of EGFR-Tyrosine Kinase Inhibition in Clinical Samples <i>Shazli N. Malik, Roble G. Bedolla, Manuel Hidalgo, Michael G. Brattain, and Jeffrey I. Kreisberg</i>	135
13	Immunohistochemical Assays of Farnesyltransferase Inhibition in Patient Samples <i>Alex A. Adjei</i>	141
PART V. PROTEIN CHAPERONING/DEGRADATION PROTOCOLS		
14	Assays for HSP90 and Inhibitors <i>Wynne Aherne, Alison Maloney, Chris Prodromou, Martin G. Rowlands, Anthea Hardcastle, Katherine Boxall, Paul Clarke, Michael I. Walton, Laurence Pearl, and Paul Workman</i>	149
15	Assays for Proteasome Inhibition <i>Peter J. Elliott, Teresa A. Soucy, Christine S. Pien, Julian Adams, and Eric S. Lightcap</i>	163
PART VI. PROTEIN–PROTEIN AND PROTEIN–DNA INTERACTIONS		
16	The Mammalian Two-Hybrid Assay for Detection of Coactivator–Nuclear Receptor Interactions <i>Curtis M. Tyree and Kay Klausing</i>	175
17	Preparation of DNA–Protein Complexes Suitable for Spectroscopic Analysis <i>Nouri Neamati, Manisha Murthy, and Yun-Xing Wang</i>	185
PART VII. ANTISENSE		
18	Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression <i>Ruiwen Zhang and Hui Wang</i>	205
PART VIII. GENOMICS		
19	Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms <i>Christine M. Rose, Sharon Marsh, Margaret-Mary Ameyaw, and Howard L. McLeod</i>	225

20	Gene Expression Microarrays <i>Christopher P. Kolbert, William R. Taylor, Kelly L. Krajnik, and Dennis J. O’Kane</i>	239
21	Methods for Isolation and Genetic Analysis of Circulating Tumor DNA in Patient Plasma <i>Tomoya Kawaguchi, Will S. Holland, and Paul H. Gumerlock</i>	257
PART IX. CELL LIFESPAN/LONGEVITY		
22	The Use of Early Sea Urchin Embryos in Anticancer Drug Testing <i>David Nishioka, Vanessa Marcell, Meghan Cunningham, Merium Khan, Daniel D. Von Hoff, and Elzbieta Izbicka</i>	265
PART X. IN VIVO IMAGING		
23	PET Screening of Anticancer Drugs: <i>A Faster Route to Drug/Target Evaluations In Vivo</i> <i>Anna Fredriksson and Sharon Stone-Elander</i>	279
PART XI. MISCELLANEOUS PROTOCOLS		
24	Assays for In Vitro and In Vivo Synergy <i>Beverly A. Teicher</i>	297
25	Flow Cytometric Methods for Detection and Quantification of Apoptosis <i>David P. Steensma, Michael Timm, and Thomas E. Witzig</i>	323
26	Assays for Neoplastic Cell Enrichment in Bone Marrow Samples <i>Rafael Fonseca and Gregory J. Ahmann</i>	333
	Index	343



<http://www.springer.com/978-0-89603-963-6>

Novel Anticancer Drug Protocols

Buolamwini, J.K.; Adjei, A.A. (Eds.)

2003, XVI, 355 p., Hardcover

ISBN: 978-0-89603-963-6

A product of Humana Press